sICAM-1 w surowicy chorych na alergiczny nieżyt nosa leczonych feksofenadyną lub flutykazonem

The aim of the study was to examine the level of sICAM-1in serum of patients suffering from allergic rhinitis treated with fexofenadine or fluticasone. The study was performed after two weeks duration of the pollen season. Thirty -eight patients sensitized to grass pollen were participated in this study: 15 patients were treated for 10 days with oral fexofenadine (dose: 120 mg/d), 13 patients were treated with intranasal fluticasone (dose:200mcg/d), 10 patients were given oral placebo. Blood sample were collected both in the first and the last day of the treatment. The efficacy was evaluated with the use of symptom score. sICAM-1l level in serum was measured with ELISA method. The results: Mean sICAM-1 level in serum was: in group treated with fexofenadine- 224,5 ng/ml before treatment, 228 ng/ml – after treatment; in group treated with fluticasone-212ng/ml before treatment, 214ng/ml– after treatment; in placebo group- 226 ng/ml before treatment, 229 ng/ml– after treatment. There was no difference in statistical analysis between sICAM-1 values. (p>0,05). In 7 patients treated with fexofenadine serum levels of sICAM-1 significantly decreased from 212ng/ml to 185ng/ml(